Rhythm Pharmaceuticals (RYTM) Lifted to Hold at BidaskClub
BidaskClub upgraded shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning.
Several other research analysts have also recently issued reports on the stock. Bank of America assumed coverage on shares of Rhythm Pharmaceuticals in a report on Monday, October 30th. They set a buy rating and a $30.00 price target for the company. Cowen reissued a buy rating and set a $40.00 price target on shares of Rhythm Pharmaceuticals in a report on Tuesday, November 14th. Needham & Company LLC reissued a buy rating and set a $32.00 price target on shares of Rhythm Pharmaceuticals in a report on Tuesday, November 14th. Finally, Morgan Stanley assumed coverage on shares of Rhythm Pharmaceuticals in a report on Monday, October 30th. They set an equal weight rating and a $23.00 price target for the company. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $31.25.
Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) traded up $0.10 during trading hours on Tuesday, hitting $29.14. 24,700 shares of the stock were exchanged, compared to its average volume of 78,000. Rhythm Pharmaceuticals has a 1-year low of $21.38 and a 1-year high of $33.81.
ILLEGAL ACTIVITY NOTICE: “Rhythm Pharmaceuticals (RYTM) Lifted to Hold at BidaskClub” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://theolympiareport.com/2018/01/24/rhythm-pharmaceuticals-rytm-lifted-to-hold-at-bidaskclub.html.
Rhythm Pharmaceuticals Company Profile
Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.